Top Page
Grand Pharmaceutical Group Limited
(0512)
Grand Pharmaceutical Group Limited (0512) vs. iShares MSCI Hong Kong ETF (EWH)
Grand Pharmaceutical Group Limited Business Overview & Revenue Model
Grand Pharmaceutical Group Limited Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 11.64B | 10.53B | 9.56B | 8.60B | 6.35B |
| Gross Profit | 6.74B | 6.52B | 5.95B | 5.25B | 4.04B |
| EBITDA | 3.39B | 2.97B | 3.09B | 3.10B | 2.41B |
| Net Income | 2.47B | 1.88B | 2.08B | 2.40B | 1.79B |
Balance Sheet | |||||
| Total Assets | 24.99B | 22.52B | 22.37B | 21.06B | 16.98B |
| Cash, Cash Equivalents and Short-Term Investments | 3.14B | 2.47B | 2.48B | 2.87B | 2.39B |
| Total Debt | 4.44B | 3.40B | 4.48B | 3.65B | 2.39B |
| Total Liabilities | 8.47B | 7.24B | 8.16B | 7.61B | 5.64B |
| Stockholders Equity | 16.47B | 15.16B | 14.14B | 13.39B | 11.24B |
Cash Flow | |||||
| Free Cash Flow | 1.28B | 1.93B | 245.79M | 1.49B | 1.31B |
| Operating Cash Flow | 1.90B | 2.42B | 1.92B | 2.12B | 1.78B |
| Investing Cash Flow | -2.00B | -515.75M | -2.58B | -2.05B | -2.05B |
| Financing Cash Flow | 29.96M | -1.89B | 464.49M | -195.08M | 899.79M |
Grand Pharmaceutical Group Limited Technical Analysis
Grand Pharmaceutical Group Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | HK$30.63B | 12.24 | 15.61% | 3.01% | 10.59% | 31.83% | |
51 Neutral | $7.41B | 0.36 | -61.88% | 2.33% | 16.99% | 1.69% | |
| £1.95B | 64.41 | 5.02% | ― | ― | ― | ||
| $3.44B | 9.10 | 19.62% | 4.91% | ― | ― | ||
| $3.73B | 10.08 | 10.17% | 0.48% | ― | ― | ||
| $4.18B | 11.77 | 14.56% | 0.58% | ― | ― | ||
| €3.54B | 8.03 | 6.90% | ― | ― |
Grand Pharmaceutical Group Limited Corporate Events
Grand Pharmaceutical Group Limited announced the completion of patient enrollment for its Phase III clinical trial of CBT-001, an innovative ophthalmic drug for treating pterygium. This milestone is significant for the company’s strategic focus on ophthalmology, as CBT-001 has shown promising results in earlier trials and addresses a major unmet need in pterygium treatment. The company holds exclusive rights to produce and commercialize CBT-001 in several regions, enhancing its competitive edge in the market. Additionally, Grand Pharmaceutical is expanding its innovative product pipeline and strengthening its marketing network to support sustainable growth.
Grand Pharmaceutical Group Limited announced that its innovative ophthalmic product, GPN01768, has been approved for commercialization by the Pharmaceutical Administration Bureau of Macao, China. This approval is expected to pave the way for further approvals in the Guangdong-Hong Kong-Macao Greater Bay Area and Mainland China, addressing the urgent clinical need for effective treatment of Demodex blepharitis, a common ophthalmic disease. The company has made significant progress in its research and development pipeline, aiming to strengthen its position in the ophthalmology sector and expand its market presence with a series of innovative products.
Grand Pharmaceutical Group Limited has announced that its nuclear medicine R&D and production base in Chengdu has obtained a Class A ‘Radiation Safety License’ and will soon commence operations. This development marks a significant milestone in the company’s strategy to become a global leader in nuclear medicine, enhancing its capabilities in isotope production and nuclear medicine preparation. The base, with an investment of over RMB 3 billion, features advanced technological breakthroughs and aims to set new safety benchmarks in the industry. It will support the company’s global strategy by providing a closed-loop system for R&D, production, and sales, and will contribute to the development of high-value nuclear medicine products, strengthening its position in the global market.
Grand Pharmaceutical Group Limited announced the completion of patient enrollment and dosing for its Phase III clinical trial of TLX591-CDx, a diagnostic radiopharmaceutical for prostate cancer, in China. The New Drug Application is scheduled for submission this year, marking significant progress in the company’s nuclear medicine segment. The product, already commercialized in multiple countries, is expected to enhance the company’s market position and provide integrated diagnosis and treatment solutions for prostate cancer in China.
Grand Pharmaceutical Group Limited announced that its investigational new drug application for the radionuclide-drug conjugate TLX591, aimed at treating prostate cancer, has been accepted for an international Phase III clinical trial by China’s National Medical Products Administration. This development marks a significant advancement in the company’s nuclear medicine segment, which is focused on providing integrated diagnostic and therapeutic solutions for prostate cancer. The trial will evaluate TLX591’s efficacy and safety in combination with standard care for patients with metastatic castration-resistant prostate cancer. The innovative design of TLX591, which requires a shorter treatment cycle and offers safety advantages, positions it as a potential new standard in prostate cancer treatment, addressing clinical challenges associated with existing therapies.
Grand Pharmaceutical Group Limited announced the successful completion of a Phase II clinical study in China for its innovative drug STC3141, aimed at treating sepsis. This breakthrough positions the company at the forefront of sepsis research, offering a novel approach by targeting immune homeostasis, potentially revolutionizing treatment options for this critical condition. The study demonstrated significant improvements in patient outcomes, confirming the drug’s efficacy and safety, and paving the way for further regulatory discussions to expedite its availability to patients.
Grand Pharmaceutical Group Limited announced that its Phase II clinical study of the innovative drug STC3141 for sepsis treatment in China has successfully reached its clinical endpoint. This development marks a significant advancement in sepsis treatment by targeting immune homeostasis, addressing a major clinical gap. The study demonstrated the drug’s effectiveness and safety, with significant improvements in patient outcomes compared to the placebo. The company plans to seek breakthrough therapeutic drug designation from Chinese regulators, highlighting its strong R&D capabilities and the urgent need for targeted sepsis treatments.
Grand Pharmaceutical Group Limited has announced the first commercial prescription of UI-SEEK, an early detection product for urinary system tumors, in Mainland China. This product, developed with AcornMed, is the first of its kind in China to use a dual mechanism of methylation and gene mutation for non-invasive tumor diagnosis. The company aims to strengthen its market position in urological tumor diagnosis and expand its product portfolio to meet clinical needs in early detection and treatment of various cancers.
Grand Pharmaceutical Group Limited announced a Business Collaboration Agreement between its subsidiary Chengdu Shetai and Sirtex Medical US. This agreement allows both parties to engage each other for services related to research and development of medical device and radiopharmaceutical products, with a financial cap of US$1.2 million annually. The collaboration is expected to enhance the company’s capabilities in clinical development and logistics support, potentially strengthening its position in the medical industry.
Grand Pharmaceutical Group Limited announced the approval for commercialization of its first generic fluticasone propionate nasal spray in China, marking a significant milestone in its respiratory product line. This approval addresses a substantial unmet need in the Chinese market for allergic rhinitis treatment, a condition affecting nearly 250 million people in China. The product’s inclusion in the National Medical Insurance Catalogue and the National Essential Medicines Catalogue highlights its potential impact. The company aims to break the market monopoly of foreign-funded products and strengthen its position in the respiratory disease treatment market.
Grand Pharmaceutical Group Limited has announced a significant breakthrough in the clinical study of its innovative radionuclide-drug conjugate, GPN02006, for diagnosing hepatocellular carcinoma (HCC) in China. The study demonstrated excellent safety and imaging efficacy, showing potential to improve early diagnosis and monitoring of HCC, which is crucial given the high incidence and mortality rates associated with liver cancer. This advancement further solidifies the company’s leading position in nuclear medicine and its commitment to advancing global R&D efforts for GPN02006, aiming for simultaneous clinical studies in China and the United States.
Grand Pharmaceutical Group Limited announced the successful passing of all resolutions at its Annual General Meeting held on April 10, 2025. Key resolutions included the adoption of financial statements, declaration of a final dividend, re-election of directors, and granting of general mandates for share issuance and repurchase. The results reflect strong shareholder support and are expected to positively impact the company’s governance and operational strategies.
Grand Pharmaceutical Group Limited announced a final ordinary dividend of HKD 0.26 per share for the financial year ending December 31, 2024. The payment date for the dividend is set for April 28, 2025, following shareholder approval on April 10, 2025. This announcement reflects the company’s continued commitment to providing shareholder value.